Kevin Outterson

Professor of Law

N. Neal Pike Scholar in Health and Disability Law
Executive Director of CARB-X

University of Reading, Rotary Scholar
BS, Northwestern University
JD, Northwestern University
LLM, University of Cambridge

Areas of Interest
Health Law, Intellectual Property
Contact
  • Office Room 1604C
  • Phone 617-353-3103
Biography

Professor Kevin Outterson teaches health law and corporate law at Boston University, where he co-directs the Health Law Program, currently ranked #5 in the country by US News and World Report. He is the executive director of Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X), a global partnership hosted at BU Law that is focused on supporting developers of promising new antibiotics, diagnostics, and vaccines that tackle the threat of untreatable bacterial infections. CARB-X has built the world’s largest and most innovative antibacterial pipeline, with $480 million in grant funding from three governments (US, UK, and Germany) and two foundations (Wellcome Trust and the Bill & Melinda Gates Foundation). He also leads the Social Innovation on Drug Resistance program at Boston University.

His research focuses on the organization and finance of the health sector. Areas of specialization include global pharmaceutical markets, particularly antibiotics and other antimicrobials that can degrade in usefulness over time through resistance. He participated in a grant from the European Union’s Innovative Medicines Initiative to study business models and incentives for antibiotic development. He leads an interdisciplinary project on the legal ecology of antimicrobial resistance, funded in part by the Robert Wood Johnson Foundation program on public health law. He is an associate fellow at the Royal Institute of International Affairs at Chatham House, London, where he works on global solutions to antibiotic resistance, and an appointed member of the Antimicrobial Resistance Working Group at the Centers for Disease Control.

Professor Outterson has testified before President Obama’s Advisory Council on Combating Antibiotic Resistance, where he presented the results of a two-year study sponsored by the European Union on designing economic incentives for antibiotic development.

  • Click here for a BU Research interview about Professor Outterson’s work on antibiotic resistance.
  • Click here for a 2020 profile of his leadership of CARB-X in the Boston Globe.

Another significant body of work critiques access and equity issues created by global patent and drug regulation laws. Key texts in this debate include the WTO TRIPS Agreement and related trade agreements. His academic papers can be found on his Google Scholar page. He tweets about antibacterial R&D @koutterson.

Professor Outterson publishes in both legal journals (Yale Journal of Health Policy, Law & Ethics; Cardozo Law Review; University of Pittsburgh Law Review; Kansas Law Review; American Journal of Law & Medicine) and peer-reviewed medical and health policy journals (New England Journal of Medicine; Health Affairs; Lancet Infectious Diseases; Environmental Philosophy; Medical Journal of Australia; Journal of Generic Medicines; Clinical Infectious Diseases; Journal of Law, Medicine & Ethics).

On behalf of The New England Journal of Medicine and other clients, Outterson filed an amicus brief in the US Supreme Court, supporting Vermont’s prescription privacy law. His work was cited by Justice Breyer in Sorrell v. IMS Health. A team led by Professors Outterson and Moncrieff at Boston University filed four amicus briefs supporting the Affordable Care Act, which was heard by the Court in the spring of 2012.

He is the immediate past editor-in-chief of the Journal of Law, Medicine & Ethics; current faculty co-advisor to the American Journal of Law & Medicine; past chair of the Section on Law, Medicine & Health Care of the AALS; and the former President and member of the Board of the American Society of Law, Medicine & Ethics. Professor Outterson served on the Advisory Panel for the Longitude Prize, focused on diagnostic innovation against drug-resistant bacteria. Before teaching, Outterson was a partner at two major US law firms.

 

 

Publications
  1. Kevin Outterson & John H. Rex, "Antibacterial R&D at a crossroads: We’ve pushed as hard as we can...now we need to start pulling!" Clinical Infectious Diseases (forthcoming).
  2. Kevin Outterson, Helen Boucher, Thomas File, Vance Fowler, Amanda Jezek & John H. Rex, "Antibiotic Development Incentives That Reflect Societal Value of Antibiotics," Clinical Infectious Diseases (forthcoming).
    Publisher
  3. Kevin Outterson & John H. Rex, "Evaluating for-profit public benefit corporations as an additional structure for antibiotic development and commercialization," 220 Translational Research 182 (2020).
    Publisher
  4. Claas Kirchhelle, Steven J. Hoffman, Javier Lezaun, Susan Nayiga, Kevin Outterson, Scott Podolsky, Stephanie Raymond, Adam P. Roberts, Andrew C. Singer, Anthony D. So, Luechai Sringernyuang, Paul Atkinson, Elizabeth Tayler, Susan Rogers Van Katwyk, Clare Chandler, Alex Broom, Komatra Chuengsatiansup, Jorge Pinto Ferreira, Nicolas Fortané, Isabel Frost, Christoph Gradmann & Stephen Hinchliffe, "Setting the Standard: Multidisciplinary Hallmarks for Structural, Equitable and Tracked Antibiotic Policy," 5 BMJ Global Health e003091 (2020).
    Publisher | Scholarly Commons
  5. Kevin Outterson, Marc Mendelson, Sharon Peacock, Yong-Guan Zhu, Ramanan Laxminarayan, Thomas Van Boeckel, Isabel Frost, Samuel Kariuki, Ejaz Khan, Direk Limmathurotsakul, D G Joakim Larsson & Gabriel Levy-Hara, "The Lancet Infectious Diseases Commission on antimicrobial resistance: 6 years later," 20 Lancet Infectious Diseases e51 (2020).
    Publisher
  6. Kevin Outterson, Christine Årdal, Manica Balasegaram, Ramanan Laxminarayan, David McAdams, John H. Rex & Nithima Sumpradit, "Antibiotic development — economic, regulatory and societal challenges," Nature Reviews Microbiology (2019).
    Publisher
  7. Kevin Outterson, John H. Rex, Holly Fernandez Lynch, I. Glenn Cohen & Jonathan J. Darrow, "Designing development programs for non-traditional antibacterial agents," 10(1) Nature Communications 3416 (2019).
    SSRN | Scholarly Commons
  8. Kevin Outterson, Tamar Barlam, Jake Morgan, Warren Kaplan & Stephen Pelton, "Disproportionate Exposure to Antibiotics in Children at Risk for Invasive Pneumococcal Disease: Potential for Emerging Resistance and Opportunity for Antibiotic Stewardship," 8 Journal of the Pediatric Infectious Diseases Society 63 (2019).
  9. Kevin Outterson, Ursula Theuretzbacher, Aleks Engel & Anders Karlén, "The global preclinical antibacterial pipeline," 18 Nature Reviews Microbiology 275 (November 2019).
    Publisher
  10. Kevin Outterson, Joanne Liu, Muhammad Pate, Mathieu Poirier, John-Arne Rottingen, Julian Savulescu, Rebecca Sugden, Visanu Thamlikitkul, Isaac Weldon, Sally Davies, Steven J. Hoffman, Susan Rogers Van Katwyk, Manica Balasegaram, Pete Boriello, Jeremy Farrar, Alberto Giubilini, Mark Harrison, Marie-Paule Kieny & Claas Kirchhelle, "A roadmap for sustainably governing the global antimicrobial commons," 394 The Lancet 1788 (2019).
    Publisher
  11. Kevin Outterson, "A shot in the arm for new antibiotics," 37 Nature Biotechnology 1110 (2019).
    Publisher
  12. Kevin Outterson, Innovative ways to pay for new antibiotics will help fight superbugs. STAT (April 11, 2018). Publisher
  13. Kevin Outterson, Céline Pulcini, Gunnar Kahlmeter, Jean Patel, Jan Kluytmans, Marc Ouellette, Marco Cavaleri, Paul Hansen, Edward M Cox, Chris R Houchens, M Lindsay Grayson, Evelina Tacconelli, Nalini Singh, Elena Carrara, the WHO Pathogens Priority List Working Group, Ursula Theuretzbacher, Nicola Magrini, Marc Mendelson, Alessia Savoldi, Stephan Harbarth, Dominique L Monnet & Yehuda Carmeli, "Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis," 18 Lancet Infectious Diseases 318 (2018).
    Publisher | Scholarly Commons
  14. Kevin Outterson, Christine Årdal, Enrico Baraldi, Ursula Theuretzbacher, Jens Plahte, Francesco Ciabuschi & John-Arne Rottingen, "Insights into early stage of antibiotic development in small- and medium-sized enterprises: a survey of targets, costs, and durations," 11 Journal of Pharmaceutical Policy and Practice 8 (2018).
    SSRN | Scholarly Commons
  15. Kevin Outterson, Cecilia Kållberg, Christine Årdal, Hege Salvesen Blix, Elli Klein, Morten Lindbæk, John-Arne Rottingen & Ramanan Laxminarayan, "Introduction and geographic availability of new antibiotics approved between 1999 and 2014," 13(10) PLOS ONE 19 pages (2018).
    Publisher
  16. Kevin Outterson, Nicole Huberfeld & Elizabeth Weeks, The Law of American Health Care, 2nd, Aspen Publishers (2018).
  17. Kevin Outterson, Taimur Bhatti, Ka Lum, Silas Holland, Stephanie Sassman & David Findlay, "A Perspective on Incentives for Novel Inpatient Antibiotics: No One-Size-Fits-All," 46 Journal of Law, Medicine & Ethics 59 (2018).
    Publisher
  18. Kevin Outterson, Christine Årdal, David Findlay, Miloje Savic, Yehuda Carmeli, Inge Gyssens, Ramanan Laxminarayan & John H. Rex, Revitalizing the antibiotic pipeline: Stimulating innovation while driving sustainable useand global access, DRIVE-AB Final Report (European Commission, Innovative MedicinesInitiative), (2018).
    Publisher
  19. Kevin Outterson, Dalia Deak, John H. Powers III & Aaron S. Kesselheim, "The Fight Against Multidrug-Resistant Bacteria," 166 Annals of Internal Medicine 79 (2017).
    Publisher
  20. Kevin Outterson, Ursula Theuretzbacher, Miloje Savic & Christine Årdal, "Innovation in the preclinical antibiotic pipeline," 16 Nature Reviews Drug Discovery 744 (2017).
    Publisher
  21. Kevin Outterson, Nicole Huberfeld & Elizabeth Weeks, "Teaching the Law of American Health Care," 61 Saint Louis University Law Journal 401 (2017).
    Publisher | Scholarly Commons | HeinOnline
  22. Kevin Outterson, Christine Årdal, Enrico Baraldi, Francesco Ciabuschi, John H. Rex, Laura Piddock & David Findlay, "To the G20: incentivising antibacterial research and development," 17 Lancet Infectious Diseases 799 (2017).
    Publisher
  23. Kevin Outterson & Nicholas Bagley, We will miss antibiotics when they’re gone. NY Times, OpEd, (Jan.18, 2017). Publisher
  24. Kevin Outterson, Testimony before the Massachusetts Joint Committee on Health Care Financing (on drugprice transparency) (April 11, 2016).
  25. Kevin Outterson, Testimony before the United Nations High-Level Panel on Access to Medicines, (Antibiotic Delinkage; London, England) (Feb. 28, 2016).
  26. Kevin Outterson, John H. Rex et al., "Accelerating Global Innovation to Address Antibacterial Resistance: Introducing CARB-X," 15 Nature Reviews Drug Discovery 589 (2016).
    Publisher
  27. Kevin Outterson & John H. Rex, "Antibiotic Reimbursement in a Model Delinked from Sales: A Benchmark-based Worldwide Approach," 16 Lancet Infectious Diseases 500 (2016).
    Publisher | SSRN | Scholarly Commons
  28. Kevin Outterson & Anthony McDonnell, "Antimicrobial Resistance: The Authors Reply," 35 Health Affairs 1936 (2016).
    Publisher
  29. Kevin Outterson, Unni Gopinathan, Charles Clift, Anothy D. So, Chantel M. Morel & John-Arne Rottingen, "Delinking Investment in Antibiotic R&D from Sales Revenues: The Challenges of Transforming a Promising Idea into Reality," 13 PloS Medicine 7 pages (2016).
    Publisher | Scholarly Commons
  30. Kevin Outterson & Anthony McDonnell, "Funding Antibiotic Innovation with Vouchers: Recommendations on How to Strengthen A Flawed Incentive Policy.," 35 Health Affairs 784 (2016).
    Publisher | SSRN | Scholarly Commons
  31. Kevin Outterson et al., "International Cooperation to Improve Access to and Sustain Effectiveness of Antimicrobials," 387 Lancet 296 (Jan 16-22, 2016).
    SSRN | Scholarly Commons
  32. Kevin Outterson, Nicole Huberfeld & Elizabeth Weeks, The Law of American Health Care, 1st, Aspen Publishers (2016).
  33. Kevin Outterson, Dalia Deak, John H. Powers III & Aaron S. Kesselheim, "Progress in the Fight Against Multidrug Resistant Bacteria?: A Review of FDA-Approved Antibiotics 2010-2015," 165 Annals of Internal Medicine 363 (2016).
    Publisher
  34. Kevin Outterson, E. Jaczynska & J. Mestre-Ferrandiz, Business Model Options for Antibiotics: Learning from Other Industries, Chatham House Centre for Global Health Security & The Big Innovation Centre, (Feb 2015).
    SSRN | Scholarly Commons
  35. Kevin Outterson et al., "An International Legal Framework to Address Antimicrobial Resistance," 93 Bulletin of the WHO 66 (Feb 2015).
    SSRN | Scholarly Commons
  36. Kevin Outterson, John H. Powers III, Gregory W. Daniel & Mark B. McClellan, "Repairing the Broken Market for Antibiotic Innovation," 34 Health Affairs 277 (Feb 2015).
    SSRN | Scholarly Commons
  37. Kevin Outterson, Charles Clift, Unni Gopinathan, Chantel M. Morel, John-Arne Rottingen & Anothy D. So, Report from the Chatham House Working Group on New Antibiotic Business Models, Chatham House Centre for Global Health Security, (Mar 2015).
  38. Kevin Outterson & Steven J. Hoffman, "What Will It Take to Address the Global Threat of Antibiotic Resistance?" 43 Journal of Law, Medicine and Ethics 363 (2015).
    SSRN | Scholarly Commons
  39. Kevin Outterson, AHLA Health Law Curriculum Manual, Kevin Outterson, ed., American Health Lawyers Association (2014).
    Publisher
  40. Kevin Outterson et al., Analytical Framework for Examining the Value of Antibacterial Products, US Department of Health & Human Services / ASPE, (Apr 15, 2014).
    SSRN | Publisher | Scholarly Commons
  41. Kevin Outterson, "Clinical Trial Transparency - Antidote to Increased Off-label Promotion?" 371 New England Journal of Medicine 1 (2014).
  42. Kevin Outterson, "The Drug Quality and Security Act - Mind the Gaps," 370 New England Journal of Medicine 97 (2014).
    SSRN | Scholarly Commons
  43. Kevin Outterson, John H. Powers III, Enrique Seoane-Vazquez, Rosa Rodriguez-Monguio & Aaron S. Kesselheim, "Approval and Withdrawal of New Antibiotics and Other Antiinfectives in the U.S., 1980-2009," 41 Journal of Law, Medicine and Ethics 688 (2013).
    SSRN | Scholarly Commons
  44. Kevin Outterson, T. Pogge & A. Hollis, "Combating Antibiotic Resistance Through the Health Impact Fund," in The Globalization of Health Care: Legal and Ethical Issues 318, I. Glenn Cohen, ed., Oxford University Press (2013). SSRN | Scholarly Commons
  45. Kevin Outterson, Nicole Huberfeld & E. W. Leonard, "Plunging into Endless Difficulties: Medicaid and Coercion in National Federation of Independent Business v. Sebelius," 93 Boston University Law Review 1 (2013).
    SSRN | HeinOnline (BU) | HeinOnline | Scholarly Commons
  46. Kevin Outterson & C. B. Eisenberg, "Agents Without Principals: Regulating the Duty of Loyalty for Non Profit Corporations Through the Intermediate Sanctions Tax Regulations," 5 Pepperdine Journal of Business Entrepreneurship & the Law 243 (2012).
    BU
  47. Kevin Outterson, "All Pain, No GAIN: Need for Prudent Antimicrobial Use Provisions to Complement the GAIN Act," 30:1 APUA Clinical Newsletter 13 (2012).
    Publisher | BU | SSRN | Scholarly Commons
  48. Kevin Outterson, Amici Curiae Brief on Behalf of the Department of Health and Human Services, DHHS v. Florida, U.S. Supreme Court, No. 11-398 (Jan 13, 2012). [ACA litigation, minimum coverage provision]
    SSRN | Scholarly Commons
  49. Kevin Outterson, Nicole Huberfeld, Laura D. Hermer, Elizabeth Weeks, Sara Rosenbaum & Sidney D. Watson, Amici Curiae Brief on Behalf of the Department of Health and Human Services, Florida v. DHHS, U.S. Supreme Court, (Feb 17, 2012).
    SSRN | Scholarly Commons
  50. Kevin Outterson & S. Speiser, "Deductions for Drug Ads? The Constitution Does Not Require Congress to Subsidize Direct-To-Consumer Prescription Drug Advertisements," 52 Santa Clara Law Review 453 (2012).
    BU | SSRN | Scholarly Commons
  51. Kevin Outterson, Evan Selinger & Kyle Whyte, "Poverty Tourism, Justice, and Policy: Can Ethical Ideals Form the Basis of New Regulations?" 14 Public Integrity 39 (2011-12).
    BU | SSRN | Scholarly Commons
  52. Kevin Outterson, "Regulating Compounding Pharmacies after NECC," 367 New England Journal of Medicine 1969 (Nov 22, 2012).
  53. Kevin Outterson, Blog Posts Incidental Economist (2011).
  54. Kevin Outterson & Austin Frakt, "After the Deluge: Health Reform Without an Individual Mandate," Kaiser Health News (Feb 24, 2011).
    Publisher
  55. Kevin Outterson, Amici Curiae Brief on Behalf of the New England Journal of Medicine, the Massachusetts Medical Society, the National Physicians Alliance, and the American Medical Students Association in Sorrell v. IMS Health Inc., U.S. Supreme Court, (Mar 1, 2011). [defending Vermont’s data mining law]
    SSRN
  56. Kevin Outterson & Olga Yevtukhova, "Germ Shed Management in the United States," in Antibiotic Policies: Controlling Hospital Acquired Infection 163, Ian M. Gould & Jos van der Meer, eds., Springer (2011). SSRN
  57. Kevin Outterson, "Higher First Amendment Hurdles for Public Health Regulation," 365 New England Journal of Medicine e13 (2011).
  58. Kevin Outterson & Aaron S. Kesselheim, "Improving Antibiotic Markets for Long Term Sustainability," 11 Yale Journal of Health Policy, Law & Ethics 101 (2011).
    SSRN | Scholarly Commons
  59. Kevin Outterson, Kyle Whyte & Evan Selinger, "Poverty Tourism and the Problem of Consent," 7 Journal of Global Ethics 337 (2011).
    SSRN | Scholarly Commons
  60. Kevin Outterson, "Smoking and the First Amendment," 365 New England Journal of Medicine 2351 (2011).
  61. Kevin Outterson, Anothy D. So et al., "Towards New Business Models for R&D for Novel Antibiotics," 14 Drug Resistance Updates 88 (2011).
  62. Kevin Outterson, "Disease-Based Limitations on Compulsory Licenses Under Articles 31 and 31bis," in Research Handbook on the Protection of Intellectual Property Under WTO Rules 673, Carlos Correa, ed., Edward Elgar Pub (2010). SSRN
  63. Kevin Outterson & Evan Selinger, "The Ethics of Poverty Tourism," 7:2 Environmental Philosophy 93 (2010).
    SSRN | Scholarly Commons
  64. Kevin Outterson & Aaron S. Kesselheim, "Fighting Antibiotic Resistance: Marrying New Financial Incentives To Meeting Public Health Goals," 29 Health Affairs 1689 (2010).
    SSRN | Scholarly Commons
  65. Kevin Outterson, "The Legal Ecology of Resistance: The Role of Antibiotic Resistance in Pharmaceutical Innovation," 31 Cardozo Law Review 613 (2010).
    SSRN | Scholarly Commons
  66. Kevin Outterson, John H. Powers III, Ian M. Gould & Aaron S. Kesselheim, "Questions About the 10 x '20 Initiative," 51 Clinical Infectious Diseases 751 (2010).
  67. Kevin Outterson & Aaron S. Kesselheim, "Superbugs Call for Super Changes in Drug Sale Rules," Boston Globe A11 (Nov. 15, 2010).
  68. Kevin Outterson, Pharmaceutical Innovation: Law & the Public's Health v.37:2 Journal of Law, Medicine & Ethics, editor (2009).
  69. Access to HPV Vaccines: Human Rights and Global Health, 35:2 & 3, Kevin Outterson & Frances Miller, eds., American Journal of Law and Medicine (2009).
  70. Kevin Outterson, Amici Curiae Brief on Behalf of the New England Journal of Medicine, the Vermont Medical Society, the Massachusetts Medical Society, the New Hampshire Medical Society, the National Physicians Alliance, and the American Medical Students Association, in IMS, 2nd Circuit, (2009).
    SSRN
  71. Kevin Outterson, Comments on the Physician Payment Sunshine Act of 2009, Submission to the U.S. Senate Committee on Aging, (Jan. 26, 2009).
  72. Kevin Outterson, "Death from the Public Domain?" 87 Texas Law Review See Also 45 (2009).
    SSRN | Publisher | Scholarly Commons
  73. Kevin Outterson, "Drug & Device Provisions in House Bill 3962," 15 PhRMA Pricing and Reimbursement 1 (Dec. 2009).
  74. Kevin Outterson, "The End of Reparations Talk? - Reparations in an Obama World," 57 Kansas Law Review 935 (2009).
    SSRN | Scholarly Commons
  75. Kevin Outterson, "Foreword - Will HPV Vaccines Prevent Cervical Cancers Among Poor Women of Color?: Global Health Policy at the Intersection of Human Rights and Intellectual Property Law," 35 American Journal of Law & Medicine 247 (2009).
    Westlaw | Lexis Advance | HeinOnline (BU) | HeinOnline
  76. Kevin Outterson & Paige Goodwin, "From Comparative Effectiveness to Cost Effectiveness?" 14 PhRMA Pricing and Reimbursement 126 (May 2009).
  77. Kevin Outterson & Donald Light, "Global Pharmaceutical Markets," in A Companion to Bioethics 417, 2d ed., H. Kuhse & P. Singer, eds., Blackwell (2009). SSRN
  78. Kevin Outterson & Aaron S. Kesselheim, "How Medicare Could Get Better Prices on Prescription Drugs," 28 Health Affairs W832 (2009).
    Publisher | Scholarly Commons
  79. Kevin Outterson, "Import Safety Rules And Generic Drug Markets," in Import Safety: Regulatory Governance in the Global Economy 110, C. Coglianese, A. Finkel & D. Zaring, eds., University of Pennsylvania Press (2009). SSRN
  80. Kevin Outterson, "Introduction: Pharmaceutical Innovation: Law & the Public's Health," in Symposium Pharmaceutical Innovation: Law & the Public's Health, 37 Journal of Law, Medicine & Ethics 173 (2009).
    Lexis Advance
  81. Kevin Outterson, Priority Watch List Treatment for Thailand and Brazil Under Section 182 of the Trade Act of 1974, submission to the United States Trade Representative, Docket USTR-2009-0001 (Feb. 17, 2009).
  82. Kevin Outterson, "Antibiotic Resistance and Antibiotic Development - Author's Reply," 8 Lancet Infectious Diseases 212 (2008).
    Publisher
  83. Kevin Outterson & Aaron S. Kesselheim, "Market-Based Licenses for HPV Vaccines in Developing Countries," 27 Health Affairs 130 (2008).
    Publisher
  84. Kevin Outterson, "Should Access to Medicines and TRIPS Flexibilities Be Limited to Specific Diseases?" 34 American Journal of Law and Medicine 279 (2008).
    SSRN | Scholarly Commons
  85. Kevin Outterson & Paige Goodwin, "FDA Act Creates New Incentives for Tropical Diseases, Orphan Antibiotics," 12 PhRMA Pricing and Reimbursement 350 (2007).
  86. Kevin Outterson, "International Pharmaceutical Issues," in The Fundamentals of Life Sciences Law: Drugs, Devices, and Biotech 441, American Health Lawyers Association (2007).
  87. Kevin Outterson, J. B. Samora & K. Keller-Cuda, "Will Longer Antimicrobial Patents Improve Global Public Health?" 7 Lancet Infectious Diseases 559 (2007).
    SSRN | Scholarly Commons
  88. Kevin Outterson, Access to Global Disease Innovation, submission to WHO Intergovernmental Working Group, (2006).
    SSRN
  89. Kevin Outterson & Ryan Smith, "Counterfeit Drugs: The Good, the Bad, and the Ugly," 16 Albany Law Journal of Science & Technology 525 (2006).
    SSRN | Scholarly Commons
  90. Kevin Outterson, "Fair Followers: Expanding Access to Generic Pharmaceuticals for Low- and Medium-Income Populations," in The Power of Pills: Social, Ethical and Legal Issues in Drug Development, Marketing and Pricing 164, Jillian Clare Cohen, Patricia Illingworth & Udo Schuklenk, eds., University of Michigan/Pluto Press (2006). Portuguese translation: 'Fair Followers': Expandindo o Acesso a Medicamentos Genericos para a Populacao de Baixa e Media Renda (2007).SSRN
  91. Kevin Outterson & Ilona Volker, "New Legislative Trends Threaten the Way Health Information Companies Operate," 11 PhRMA Pricing and Reimbursement 324 (2006).
  92. Kevin Outterson, "Patent Buy-Outs for Global Disease Innovations for Low- and Middle-Income Countries," 32 American Journal of Law & Medicine 159 (2006).
    SSRN | Scholarly Commons
  93. Kevin Outterson, "Agony in the Antipodes: The Generic Drug Provisions in the Australia - US Free Trade Agreement," 2 Journal of Generic Medicines 316 (2005).
    SSRN | Scholarly Commons
  94. Kevin Outterson, "Pharmaceutical Arbitrage: Balancing Access and Innovation in International Prescription Drug Markets," 5 Yale Journal of Health Policy, Law & Ethics 193 (2005).
    SSRN | Scholarly Commons
  95. Kevin Outterson, "Tragedy & Remedy: Reparations for Disparities in Black Health," 9 DePaul Journal of Health Care Law 735 (2005).
    SSRN | Scholarly Commons
  96. Kevin Outterson, "The Transparency Revolution in PhRMA Pricing," 10 PhRMA Pricing and Reimbursement 4 (2005).
  97. Kevin Outterson, "The Vanishing Public Domain: Antibiotic Resistance, Pharmaceutical Innovation and Global Public Health," 67 University of Pittsburgh Law Review 67 (2005).
    SSRN | Scholarly Commons
  98. Kevin Outterson, "Free Trade Against Free Riders?" 9 PhRMA Pricing and Reimbursement 254 (2004).
    SSRN
  99. Kevin Outterson, "Free Trade in Pharmaceuticals," 181 Medical Journal of Australia 260 (2004).
    Publisher
  100. Kevin Outterson, "Medicare Act (1965)," in Major Acts of Congress, Brian K. Landsberg, ed., MacMillan, 264 (2004).
  101. Kevin Outterson, "More Questions Than Answers: A Quick Response to the USTR Press Release on the AUSFTA," www.citizenstrade.org (2004).
    Publisher
  102. Kevin Outterson, "Pharma Under George III," 9 PhRMA Pricing and Reimbursement 352 (2004).
  103. Kevin Outterson, "Prohibition of the Slave Trade (1807)," in Major Acts of Congress, Brian K. Landsberg, ed., MacMillan, 138 (2004).
  104. Kevin Outterson, "Rapid Response to Editorial," British Medical Journal (Jun 23, 2004). Commenting on: P. Drahos & D. Henry, "The Free Trade Agreement Between Australia and the United States," 328 British Medical Journal 1271 (May 2004).
    Publisher
  105. Kevin Outterson, Amicus Brief on Behalf of Respondents in Gratz v. Bollinger and Grutter v. Bollinger on behalf of the National Coalition of Blacks for Reparations in America and the National Conference of Black Lawyers, U.S. Supreme Court, (Feb. 14, 2003). [the Michigan affirmative action cases]
  106. Kevin Outterson, "Slave Taxes," in Should America Pay?: Slavery and the Raging Debate over Reparations 135, Raymond Winbush, ed., Harper Collins (2003). Reprinted in Studies in the History of Tax Law 263, John Tiley, ed., Hart Publishing (2004).
  107. Kevin Outterson, "GP Corporatisation: Lessons Learned from the U.S. Experience," 175:8 Medical Journal of Australia 426 (2001).
  108. Kevin Outterson, "Health Care, Technology and Federalism," 103 West Virginia Law Review 503 (2000-01).
    Westlaw | Lexis Advance | HeinOnline (BU) | HeinOnline
  109. Kevin Outterson & Jennifer L. Butler, "Disease Management: Legal Strategies for the Next Generation of Managed Care," 31 Journal of Health Law 291 (1998). Updated and republished as Disease Management and Gainsharing: The Next Generation of Managed Care, with Claire F. Miley & Jennifer L. Butler, 2d ed., AHLA Monograph (1999).
  110. Kevin Outterson & Cheung, "Revenue Procedure 91-12: The IRS Launches an Information-Gathering Offensive Against International Transportation Operations," 91 Tax Notes International 71 (1991).
  111. Kevin Outterson, "Taxation Without Premeditation: An Economic Analysis of the Structure, Regulation and Strangulation of the Private Activity Bond Market," 6 Boston University Journal of Tax Law 1 (1988).
    HeinOnline (BU) | HeinOnline
Courses
In the Media
View all profiles